RxDoctor Payments Data

Katy Langstone

Family · Knoxville, TNNPI 1740910546

Payments from drug & device makers

$2,700in general payments, 2019–2025

Across 153 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$509
  • Novo Nordisk$410
  • Takeda Pharmaceuticals U.S.A., Inc.$294
  • Tris Pharma Inc$268
  • AbbVie$249
  • Intra-sana Laboratories$203
  • plus $767 from 10 others

What the payments were for

  • Food & beverage$2,700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,700 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,043
Medicare patients
12
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide166$186,807
OzempicSemaglutide41$40,219
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,415
Ondansetron OdtOndansetron33$1,096
Hydroxyzine Hcl13$334
Tizanidine Hcl12$200
Atorvastatin Calcium13$168
Gabapentin12$121
Tramadol Hcl12$117
Losartan Potassium12$96
Topiramate14$75
Levothyroxine Sodium20$75
Trazodone Hcl11$72
Sertraline Hcl22$71
Amlodipine Besylate11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$509$186,807166 claims
Novo NordiskOzempic$410$40,21941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →